US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.32 against a street estimate of -0.40 — a beat of 20.0%.
Analysts rate Scynexis Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $36.33.
| Fund | Stake |
|---|---|
| Great Point Partners LLC | 9.49% |
| Squadron Capital Management LLC | 7.61% |
| Propel Bio Management LLC | 5.46% |
| Adage Capital Partners Gp LLC | 5.46% |
| Woodline Partners LP | 3.89% |
| Vanguard Capital Management, LLC | 2.98% |
| Avidity Partners Management LP | 2.62% |
| Kingdon Capital Management LLC | 2.49% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Scynexis Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.